financetom
Business
financetom
/
Business
/
Lucid's Stock Declines as First-Quarter Results Miss Street Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lucid's Stock Declines as First-Quarter Results Miss Street Views
May 7, 2024 4:08 AM

06:30 AM EDT, 05/07/2024 (MT Newswires) -- Lucid Group ( LCID ) shares dropped early Tuesday after the electric vehicle maker delivered a wider-than-expected first-quarter loss, while overall revenue fell short of market estimates.

The company reported a per-share loss of $0.30 for the March quarter, compared with a $0.43 loss the year before, it said late Monday. The consensus on Capital IQ was for a loss of $0.25 a share. Revenue advanced to $172.7 million from $149.4 million, but trailed the Street's view for $182.5 million.

"Average selling prices were down sequentially due to mix as well as the pricing adjustments, which affected a part of the quarter," Interim Chief Financial Officer Gagan Dhingra said during a conference call, according to a Capital IQ transcript. Cost of revenue came in at $404.8 million versus $500.5 million in the prior-year quarter.

Shares of the automaker have tumbled roughly 27% so far this year and were down more than 7% in premarket activity.

Lucid delivered 1,967 vehicles during the quarter, representing annual growth of nearly 40%. The company manufactured 1,728 vehicles, down from 2,314 units in the same period last year. "Our lower production than deliveries is an active decision to be cost conscious and is not a reflection of production bottlenecks," Chief Executive Peter Rawlinson said on the call.

The EV maker is still targeting production of 9,000 vehicles for full-year 2024. "We will continue to prudently manage and adjust our production to meet our sales and delivery needs," Dhingra told analysts. The company is "pleased with the demand" it is seeing, but usually experiences "some seasonality in Saudi Arabia towards the end of the second quarter," the interim finance chief said.

Lucid expects the overhead per vehicle to "significantly improve" as it ramps up production and deliveries, according to Dhingra. In the current three-month period, it estimates its gross margin to remain flat despite a full-quarter price adjustment. "This improvement is mainly due to further cost optimization initiatives," Dhingra said.

Price: 2.8100, Change: -0.24, Percent Change: -7.87

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Halozyme Therapeutics Insider Sold Shares Worth $1,773,790, According to a Recent SEC Filing
Halozyme Therapeutics Insider Sold Shares Worth $1,773,790, According to a Recent SEC Filing
Sep 13, 2024
03:33 AM EDT, 09/13/2024 (MT Newswires) -- Helen Torley, Director, President and Chief Executive Officer, on September 10, 2024, sold 30,000 shares in Halozyme Therapeutics ( HALO ) for $1,773,790. Following the Form 4 filing with the SEC, Torley has control over a total of 676,744 shares of the company, with 676,744 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1159036/000141588924023307/xslF345X05/form4-09122024_090954.xml Price: 60.00,...
Beijing suspends PwC's China unit for six months over Evergrande audit
Beijing suspends PwC's China unit for six months over Evergrande audit
Sep 13, 2024
HONG KONG/BEIJING (Reuters) -China's Ministry of Finance (MOF) on Friday imposed a six-month business suspension on PwC's auditing unit in mainland China over its audit of troubled property developer China Evergrande Group ( EGRNF ), the regulator said. The ministry also imposed a fine of 116 million yuan ($16 million) on PwC Zhong Tian LLP, the registered accounting entity and...
Update: Immuneering Shares Surge Premarket as 'Positive' Data Seen in Phase 2a Pancreatic Cancer Trial
Update: Immuneering Shares Surge Premarket as 'Positive' Data Seen in Phase 2a Pancreatic Cancer Trial
Sep 13, 2024
04:41 AM EDT, 09/13/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Immuneering ( IMRX ) shares rose more than 30% in premarket activity Friday after saying that a complete or partial response was observed in the first two patients with first-line pancreatic cancer getting IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in a...
Sony in talks to buy Pink Floyd music rights for about $500 million, FT reports
Sony in talks to buy Pink Floyd music rights for about $500 million, FT reports
Sep 13, 2024
(Reuters) - Sony Music is in advanced talks to buy the rights to music recorded by legendary English rock group Pink Floyd for about $500 million, the Financial Times reported on Friday. Pink Floyd has been riven by personal differences between band members, notably Roger Waters and David Gilmour, that has made reaching an agreement difficult, the FT said, citing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved